Anna Braglia Endowed Young Investigator Award in Cancer Supportive Care, supported by Helsinn, awarded to Patrick Johnson, MD 24 June 2021
Aperte le preiscrizioni al Corso SSS in Tecnica dei sistemi – indirizzo chimico farmaceutica 31 May 2021
BridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQTM (infigratinib) for Patients with Cholangiocarcinoma 31 May 2021
Lonza raddoppia la produzione di vaccini – Intervista al Presidente di FIT Giorgio Calderari 30 April 2021
Helsinn Announces the Launch of Adlumiz® (anamorelin) for the Treatment of Cancer Cachexia in Japan 21 April 2021
Helsinn announces poster presentation at Academy of Managed Care Pharmacy (AMCP)2021 Virtual Meeting evaluating healthcare resource utilization in CINV 13 April 2021
BridgeBio Pharma’s Affiliate QED Therapeutics and Helsinn Group Announce Strategic Collaboration to Co-Develop and Commercialize Infigratinib in Oncology 31 March 2021
“Banche e industria, un binomio vincente nella crisi pandemica”– Tavola rotonda online, ospite il presidente di FIT Giorgio Calderari 25 March 2021
Linkedin